| Literature DB >> 30626375 |
A K Lofters1,2,3,4,5, M L McBride6,7, D Li6, M Whitehead8, R Moineddin9,10,11, L Jiang8,12, E Grunfeld9,10,11,13, P A Groome8,14,15.
Abstract
BACKGROUND: In Canada, clinical practice guidelines recommend breast cancer screening, but there are gaps in adherence to recommendations for screening, particularly among certain hard-to-reach populations, that may differ by province. We compared stage of diagnosis, proportion of screen-detected breast cancers, and length of diagnostic interval for immigrant women versus long-term residents of BC and Ontario.Entities:
Keywords: Breast cancer; Cancer screening; Diagnosis interval; Health equity; Immigrant health; Stage of diagnosis
Mesh:
Year: 2019 PMID: 30626375 PMCID: PMC6327524 DOI: 10.1186/s12885-018-5201-0
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Immigration-related characteristics of the study population in BC and Ontario
| BC | Ontario | ||
|---|---|---|---|
| N (%) | 14,198 (100) | 46,952 (100) | |
| Long-term residents | 12,520 (88.2) | 41,457 (88.3) | |
| Immigrants | 1678 (11.8) | 5495 (11.7) | |
| Region | East Asia & Pacific | 948 (6.7) | 1636 (3.5) |
| Eastern Europe & Central Asia | 121 (0.9) | 933 (2.0) | |
| Latin American & Caribbean | 64 (0.5) | 752 (1.6) | |
| Middle East & North Africa | 93 (0.7) | 513 (1.1) | |
| South Asia | 191 (1.4) | 968 (2.1) | |
| Sub-Saharan Africa | 56 (0.4) | 261 (0.6) | |
| USA/New Zealand/Australia | 68 (0.5) | 121 (0.3) | |
| Western Europe | 137 (1.0) | 311 (0.7) | |
| Immigrant Class | Economic | 961 (6.8) | 2496 (5.3) |
| Family | 609 (4.3) | 2190 (4.7) | |
| Refugee | 94 (0.7) | 699 (1.5) | |
| Other | 14 (0.1) | 110 (0.2) | |
| Years since immigration | < 10 years | 613 (4.3) | 1981 (4.2) |
| > = 10 years | 1065 (7.5) | 3514 (7.5) |
Characteristics of the study population in BC, stratified by immigrant status and region of origin
| Variable | Value | Long-term residents | Immigrants | East Asia & Pacific | Eastern Europe & Central Asia | Latin America & Caribbean | Middle East & North Africa | South Asia | Sub-Saharan Africa | USA/New Zealand/Australia | Western Europe |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | 12,520 (88.2) | 1678 (11.8) | 948 (6.7) | 121 (0.8) | 64 (0.5) | 93 (0.7) | 191 (1.4) | 56 (0.4) | 68 (0.5) | 137 (1.0) | |
| Primary care access variables | |||||||||||
| Baseline UPC index score | 0 visits | 933 (7.5) | 207 (12.3) | 117 (12.3) | 17 (14.1) | <=5 | 16–20 | 12 (6.3) | 6–10 | 6–10 | 19 (13.9) |
| 1–2 visits | 1694 (13.5) | 0 (0) | 153 (16.1) | 17 (14.1) | <=5 | <=5 | 19 (10.0) | <=5 | <=5 | 24 (17.5) | |
| UPC < =.75 (low) | 4641(37.1) | 591 (35.2) | 322 (34.0) | 42 (34.7) | 25 (39.06) | 36 (38.7) | 69 (36.1) | 19 (33.9) | 24 (35.3) | 54 (39.4) | |
| UPC > 0.75 (high) | 5252 (42.0) | 638 (38.0) | 356 (37.6) | 45 (37.2) | 28 (43.75) | 29 (31.2) | 91 (47.6) | 21 (37.5) | 28 (41.2) | 40 (29.2) | |
| Primary care visits in 6 mths prior to diagnosis | Mean ± SD | 3.3 ± 2.9 | 2.9 ± 2.4 | 2.8 ± 2.4 | 2.9 ± 2.4 | 2.6 ± 2.0 | 2.7 ± 2.4 | 2.8 ± 2.9 | 2.5 ± 1.9 | 3.0 ± 2.7 | 2.7 ± 2.4 |
| Median (IQR) | 3 (1–4) | 2 (1–4) | 2 (1–4) | 2 (1–4) | 3 (1–4) | 2 (0–5) | 3 (2–5) | 2 (1–4) | 3 (1–4) | 2 (1–4) | |
| Control variables | |||||||||||
| Age at diagnosis | Mean ± SD | 63.1 ± 13.6 | 53.4 ± 12.3 | 52.6 ± 11.8 | 54.6 ± 12.1 | 51. 8 ± 12.0 | 52.6 ± 10.9 | 54.6 ± 13.1 | 52.7 ± 13.0 | 52.1 ± 11.2 | 53.7 ± 13.3 |
| Co-morbidities (ADGs) | 0 -- 5 | 6916 (55.2) | 1092 (65.1) | 649 (68.5) | 74 (61.2) | 39 (60.9) | 58 (62.4) | 101 (52.9) | 36 (64.3) | 38 (55.9) | 97 (70.8) |
| 6 -- 9 | 4154 (33.2) | 468 (27.9) | 253 (26.7) | 37 (30.6) | 21–25 | 23 (24.7) | 65 (34.0) | 16–20 | 21–25 | 26 (19.0) | |
| 10 + | 1450 (11.6) | 118 (7.0) | 46 (4.9) | 10 (8.3) | <=5 | 12 (12.9) | 25 (13.1) | <=5 | <=5 | 14 (10.2) | |
| Income quintile | 1 (lowest) | 2247 (18.0) | 399 (23.8) | 245 (25.8) | 36 (29.8) | 16 (25) | 14 (15.1) | 53 (27.8) | 6–10 | 14 (20.6) | 11–15 |
| 2 | 2413 (19.3) | 389 (23.2) | 218 (23.0) | 23 (19.0) | 11 (17.2) | 18 (19.4) | 74 (38.7) | 6–10 | 6–10 | 30 (21.9) | |
| 3 | 2400 (19.2) | 336 (20.0) | 189 (19.9) | 23 (19.0) | 12 (18.8) | 18 (19.4) | 34 (17.8) | 17 (30.4) | 14 (20.6) | 29 (21.2) | |
| 4 | 2518 (20.1) | 247 (14.7) | 139 (14.7) | 16 (13.2) | 6–10 | 18 (19.4) | 20 (10.5) | 6–10 | 13 (19.1) | 23 (16.8) | |
| 5 | 2707 (21.6) | 257 (15.3) | 130 (13.7) | 17 (14.1) | 11–15 | 18 (19.4) | 6–10 | 16 (28.6) | 16 (23.5) | 41 (29.9) | |
| Missing | 235 (1.9) | 50 (3.0) | 27 (2.9) | 6 (5.0) | <=5 | 7 (7.53) | <=5 | 0 (0) | <=5 | <=5 | |
| Outcome variabels | |||||||||||
| Stage at diagnosis | I | 5297 (42.3) | 669 (39.9) | 396 (41.8) | 45 (37.2) | 29 (45.3) | 36 (38.7) | 51 (26.7) | 26 (46.4) | 26 (38.2) | 60 (43.8) |
| II | 3974 (31.7) | 576 (34.3) | 329 (34.7) | 43 (35.5) | 19 (29.7) | 25 (26.9) | 85 (44.5) | 15 (26.8) | 23 (33.8) | 37 (27.0) | |
| III | 1549 (12.4) | 254 (15.1) | 123 (13.0) | 23 (19.0) | 12 (18.8) | 19 (20.4) | 38 (19.9) | 8 (14.3) | 9 (13.2) | 22 (16.1) | |
| IV | 542 (4.3) | 55 (3.3) | 21 (2.2) | <=5 | <=5 | <=5 | 7 (3.66) | 6–10 | <=5 | 7 (5.1) | |
| Unknown | 1158 (9.3) | 124 (7.4) | 79 (8.3) | <=5 | <=5 | 6–10 | 10 (5.24) | <=5 | 6–10 | 11 (8.03) | |
| Screen-detected | n (%) screen-detected | 4470 (35.7) | 477 (28.4) | 259 (27.3) | 33 (27.3) | 27 (42.2) | 27 (42.2) | 61 (31.9) | 16 (28.6) | 16 (23.5) | 35 (25.6) |
| Diagnostic Interval (Screened patients) | Median (IQR) | 32 (17–55) | 30 (18–50) | 31 (18–50) | 41 (30–55) | 20 (14–45) | 26 (17–44) | 31 (16–47) | 38 (19–66) | 29 (20–51) | 28 (19–57) |
| 90th percentile | 81 | 84 | 85 | 87 | 70 | 76 | 73 | 98 | 80 | 80 | |
| Diagnostic Interval (Symptom-atic patients) | Median (IQR) | 30 (14–63) | 34 (15–72) | 35 (16–75) | 23 (11–57) | 38 (17–93) | 34 (15–73) | 41 (21–74) | 23 (11–63) | 29 (13–65) | 22 (11–69) |
| 90th percentile | 120 | 141 | 143 | 126 | 173 | 148 | 120 | 187 | 144 | 117 | |
P-value <.001 for all variables for comparison of immigrants versus long-term residents
Characteristics of the study population in Ontario, stratified by immigrant status and region of origin
| Variable | Value | Long-term residents | Immigrants | East Asia & Pacific | Eastern Europe & Central Asia | Latin American & Caribbean | Middle East & North Africa | South Asia | Sub-Saharan Africa | USA/New Zealand/Australia | Western Europe |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | 41,456 (88.3) | 5495 (11.7) | 1636 (3.5) | 933 (2.0) | 752 (1.6) | 513 (1.1) | 968 (2.1) | 261 (0.6) | 121 (0.3) | 311 (0.7) | |
| Primary care access variables | |||||||||||
| Baseline UPC index score | 0 visits | 3022 (7.3) | 565 (10.3) | 136 (8.3) | 103 (11.0) | 62 (8.2) | 91 (17.7) | 91 (9.4) | 25 (9.6) | 19 (15.7) | 38 (12.2) |
| 1–2 visits | 4496 (10.8) | 509 (9.3) | 156 (9.5) | 115 (12.3) | 65 (8.6) | 33 (6.4) | 62 (6.4) | 17 (6.5) | 18 (14.9) | 43 (13.8) | |
| UPC < =.75(low) | 10,703 (25.8) | 1796 (32.7) | 507 (31.0) | 289 (31.0) | 270 (35.9) | 160 (31.2) | 333 (34.4) | 109 (41.8) | 38 (31.4) | 90 (28.9) | |
| UPC > 0.75(high) | 23,235 (56.0) | 2625 (47.8) | 837 (51.2) | 426 (45.7) | 355 (47.2) | 229 (44.6) | 482 (49.8) | 110 (42.1) | 46 (38.0) | 140 (45.0) | |
| Primary care visits in 6 mths prior to diagnosis | Mean ± SD | 3.4 ± 3.3 | 4.0 ± 3.2 | 4.0 ± 3.0 | 3.5 ± 3.1 | 4.2 ± 3.2 | 4.2 ± 3.5 | 4.5 ± 3.4 | 3.9 ± 3.5 | 3.1 ± 3.7 | 3.2 ± 3.0 |
| Median (IQR) | 3 (1–4) | 3 (2–5) | 3 (2–5) | 3 (2–5) | 3 (2–5) | 3 (2–6) | 4 (2–6) | 3 (2–5) | 2 (1–4) | 3 (1–4) | |
| Control variables | |||||||||||
| Age at diagnosis | Mean ± SD | 61.9 ± 13.6 | 53.2 ± 12.6 | 51.8 ± 11.2 | 54.3 ± 13.1 | 53.1 ± 13.0 | 53.4 ± 12.2 | 54.6 ± 13.1 | 52.7 ± 13.0 | 52.1 ± 11.2 | 53.7 ± 13.3 |
| Co-morbidities (ADGs) | 0 -- 5 | 20,321 (49.0) | 2760 (50.2) | 823 (50.3) | 495 (53.1) | 340 (45.2) | 252 (49.1) | 471 (48.7) | 132 (50.6) | 69 (57.0) | 111 (35.7) |
| 6 -- 9 | 14,942 (36.0) | 1994 (36.3) | 617 (37.7) | 320 (34.3) | 309 (41.1) | 175 (34.1) | 355 (36.7) | 95 (36.4) | 37 (30.6) | 86 (27.7) | |
| 10 + | 6193 (14.9) | 741 (13.5) | 196 (12.0) | 118 (12.6) | 103 (13.7) | 86 (16.8) | 142 (14.7) | 34 (13.0) | 15 (12.4) | 47 (15.1) | |
| Income quintile | 1 (lowest) | 6720 (16.2) | 1411 (25.7) | 414 (25.3) | 210 (22.5) | 232 (30.9) | 124 (24.2) | 264 (27.3) | 91 (34.9) | 17 (14.0) | 59 (19.0) |
| 2 | 7917 (19.1) | 1173 (21.3) | 387 (23.7) | 167 (17.9) | 206 (27.4) | 81 (15.8) | 214 (22.1) | 39 (14.9) | 15 (12.4) | 64 (20.6) | |
| 3 | 8006 (19.3) | 1099 (20.0) | 330 (20.2) | 160 (17.1) | 147 (19.5) | 102 (19.9) | 239 (24.7) | 55 (21.1) | 20 (16.5) | 46 (14.8) | |
| 4 | 9017 (21.8) | 1032 (18.8) | 287 (17.5) | 218 (23.4) | 100 (13.3) | 112 (21.8) | 175 (18.1) | 42 (16.1) | 27 (22.3) | 71 (22.8) | |
| 5 | 9646 (23.3) | 776–780 | 211–215 | 176–180 | 67 (8.9) | 94 (18.3) | 76 (7.9) | 34 (13.0) | 42 (34.7) | 71 (22.8) | |
| Missing | 150 (0.4) | <=5 | <=5 | <=5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Outcome variables | |||||||||||
| Stage at diagnosis | I | 15,732 (37.9) | 1736 (31.6) | 586 (35.8) | 294 (31.5) | 197 (26.2) | 164 (32.0) | 250 (25.8) | 84 (32.2) | 52 (43.0) | 109 (35.0) |
| II | 14,624 (35.3) | 1983 (36.1) | 602 (36.8) | 338 (36.2) | 288 (38.3) | 197 (38.4) | 321 (33.2) | 95 (36.4) | 35 (28.9) | 107 (34.4) | |
| III | 5271 (12.7) | 837 (15.2) | 196 (12.0) | 176 (18.9) | 131 (17.4) | 73 (14.2) | 161 (16.6) | 38 (14.6) | 18 (14.9) | 44 (14.1) | |
| IV | 1849 (4.5) | 210 (3.8) | 43 (2.6) | 38 (4.1) | 43 (5.7) | 13 (2.5) | 42 (4.3) | 13 (5.0) | 6 (5.0) | 12 (3.9) | |
| Unknown | 3980 (9.6) | 729 (13.3) | 209 (12.8) | 87 (9.3) | 93 (12.4) | 66 (12.9) | 194 (20.0) | 31 (11.9) | 10 (8.3) | 39 (12.5) | |
| Screen detected | n (%) screen-detected | 11,876 (28.6) | 1081 (19.7) | 295 (18.0) | 191 (20.5) | 131 (17.4) | 121 (23.6) | 194 (20.0) | 52 (19.9) | 28 (23.1) | 69 (22.2) |
| Diagnostic Interval (Screened patients) | Median (IQR) | 28 (15–47) | 33 (19–55) | 38 (23–60) | 31 (17–49) | 33 (21–58) | 30 (20–57) | 33 (19–50) | 33 (21–49) | 22 (9–35) | 28 (13–48) |
| 90th percentile | 73 | 86 | 91 | 76 | 99 | 107 | 84 | 74 | 76 | 107 | |
| Diagnostic Interval (Symptomatic patients) | Median (IQR) | 33 (15–66) | 38 (19–76) | 44 (22–82) | 35 (16–73) | 41 (21–78) | 32 (15–73) | 35 (17–64) | 40 (19–77) | 32 (16–68) | 36 (15–77) |
| 90th percentile | 126 | 130 | 136 | 127 | 140 | 120 | 118 | 112 | 142 | 133 | |
P-value <.001 for all variables for comparison of immigrants versus long-term residents
Adjusted relative risk (ARR) of stage I/II vs. stage III/IV (reference) stage at diagnosisa
| BC | Ontario | |
|---|---|---|
| Immigrants overall |
|
|
| Long-term residents | 0.96 [0.85–1.09] | 0.98 [0.97–1.00] |
| Region of Origin | 1.0 | 1.0 |
| East Asia & Pacific |
|
|
| Eastern Europe & Central Asia | 0.86 [0.59–1.26] |
|
| Latin America & Caribbean | 0.98 [0.57–1.70] |
|
| Middle East & North Africa | 0.72 [0.48–1.09] | 1.01 [0.97–1.06] |
| South Asia | 0.79 [0.58–1.06] |
|
| Sub-Saharan Africa | 0.80 [0.47–1.36] | 0.99 [0.92–1.05] |
| USA/New Zealand/Australia | 0.91 [0.53–1.57] | 0.98 [0.89–1.09] |
| Western Europe | 0.86 [0.60–1.24] | 1.01 [0.95–1.07] |
| Long-term residents | 1.0 | 1.0 |
| Immigrant Class |
|
|
| Economic |
| 1.00 [0.98–1.03] |
| Family | 0.87 [0.73–1.04] | 0.97 [0.95–1.00] |
| Refugee | 0.98 [0.62–1.54] | 0.96 [0.92–1.00] |
| Other | 0.68 [0.28–1.65] | 1.00 [0.91–1.11] |
| Long-term residents | 1.0 | 1.0 |
| Time in Canada |
|
|
| Less than 10 years | 0.98 [0.81–1.17] | 0.99 [0.96–1.02] |
| 10 years or more | 1.08 [0.92–1.26] | 0.98 [0.96–1.00] |
| Long-term residents | 1.0 | 1.0 |
aSeparate analyses were run stratifying immigrant women by 1) region of origin, 2) immigrant class and 3) time in Canada. Control variables in all models were age at diagnosis, level of co-morbidity and neighbourhood income quintile. Significant results are bolded
Adjusted relative risk (ARR) of having a screen-detected breast cancera
| BC | Ontario | |
|---|---|---|
| Immigrants overall |
|
|
| Long-term residents |
|
|
| Region of Origin | 1.0 | 1.0 |
| East Asia & Pacific |
|
|
| Eastern Europe & Central Asia | 0.86 [0.61–1.22] | 0.89 [0.79–1.01] |
| Latin America & Caribbean | 1.34 [0.92–1.96] |
|
| Middle East & North Africa | 0.96 [0.67–1.38] | 1.00 [0.86–1.16] |
| South Asia | 0.96 [0.74–1.23] |
|
| Sub-Saharan Africa | 0.88 [0.54–1.43] | 0.94 [0.75–1.18] |
| USA/New Zealand/ Australia | 0.67 [0.41–1.10] | 1.00 [0.74–1.35] |
| Western Europe | 0.77 [0.55–1.08] | 1.09 [0.90–1.32] |
| Long-term residents | 1.0 | 1.0 |
| Immigrant Class |
|
|
| Economic | 0.91 [0.80–1.03] | 0.93 [0.86–1.00] |
| Family |
|
|
| Refugee | 0.95 [0.66–1.36] | 0.88 [0.76–1.01] |
| Other | 1.09 [0.41–2.92] | 0.94 [0.66–1.33] |
| Long-term residents | 1.0 | 1.0 |
| Time in Canada |
|
|
| Less than 10 years |
|
|
| 10 years or more | 0.91 [0.81–1.02] |
|
| Long-term residents | 1.0 | 1.0 |
aSeparate analyses were run stratifying immigrant women by 1) region of origin, 2) immigrant class and 3) time in Canada. Control variables in the models were age at diagnosis, level of co-morbidity and neighbourhood income quintile. Significant results are bolded
Adjusted difference in length of diagnostic interval measured in days at the 50th percentile, where the outcome was the length of the diagnostic interval. Long-term residents served as the reference group for each analysisa
| BC | Ontario | |
|---|---|---|
| Median [with 95% confidence intervals] | Median [with 95% confidence intervals] | |
| Immigrants overall |
|
|
| Region of origin | ||
| East Asia & Pacific |
|
|
| Eastern Europe & Central Asia | 0.4 [−5.5–6.3] |
|
| Latin America & Caribbean | 2.2 [−6.9–11.2] |
|
| Middle East & North Africa | -2 [−10.9–6.9] | 1.8 [−2.4–6.0] |
| South Asia |
|
|
| Sub-Saharan Africa | 1.0[−14.6–16.6] | 5.5 [− 1.6–12.6] |
| USA/New Zealand/ Australia | −0.3[− 12.2–11.5] | −2.5 [−7.2–2.2] |
| Western Europe | − 5[− 10.8–0.8] | 1.2 [−4.5–6.9] |
| Immigrant class | ||
| Economic | 1[− 1.3–3.3] |
|
| Family |
|
|
| Refugee | 0.2[−9.2–9.6] |
|
| Other | −9.5[−48.3–29.3] | 7 [−0.4–14.4] |
| Time in Canada | ||
| Less than 10 years | 1.4[−1.7–4.4] |
|
| 10 years or more | 2[−0.3–4.3] |
|
aSeparate analyses were run stratifying immigrant women by 1) region of origin, 2) immigrant class and 3) time in Canada. Control variables in the models were age at diagnosis, stage at diagnosis, level of co-morbidity and neighbourhood income quintile. Significant results are bolded